Linked Life Data

7768497

Source:http://linkedlifedata.com/resource/pubmed/id/7768497

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1995-6-30
pubmed:abstractText
We tested the hypothesis that a combination of sex hormone suppression and inhibition of their target receptors might improve survival for patients with hepatocellular carcinoma (HCC). Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only placebo (29 patients) in a double blind fashion. All groups were comparable as to age, sex, tumor extension, underlying cirrhosis and biochemical parameters. The tamoxifen (TMX) group had a significantly longer survival (282 days) compared with flutamide (112 days) and with placebo (127 days) groups (P = .0238, log rank test). The upper quartile of patients in the TMX group lived 384 days or longer, and most of them (57.1%) were women (P < .0005), in contrast to the upper quartile of the placebo (170 days, 16.7% women) and the flutamide group (134 days, 33.3% women). The calculated tumor volume doubling time (TVDT) was significantly higher in the TMX group (296 days) than in the other two groups (99 and 101 days for placebo and flutamide groups, respectively, P = .023). In a Cox proportional hazards model, the TMX treatment, along with the baseline Okuda's HCC stage, the hepatitis B surface antigen, the portal vein diameter, the carcino embryonic antigen (CEA) and a self-assessment score of quality of life, were covariates predicting survival. Although the degree of serum sex hormone suppression was not a significant predictor of survival, the interaction of female sex and TMX treatment, it was (P = .0052).(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0270-9139
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1535-42
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:7768497-Analysis of Variance, pubmed-meshheading:7768497-Androgens, pubmed-meshheading:7768497-Carcinoma, Hepatocellular, pubmed-meshheading:7768497-Double-Blind Method, pubmed-meshheading:7768497-Drug Therapy, Combination, pubmed-meshheading:7768497-Estradiol, pubmed-meshheading:7768497-Estrone, pubmed-meshheading:7768497-Female, pubmed-meshheading:7768497-Flutamide, pubmed-meshheading:7768497-Follicle Stimulating Hormone, pubmed-meshheading:7768497-Follow-Up Studies, pubmed-meshheading:7768497-Humans, pubmed-meshheading:7768497-Liver Neoplasms, pubmed-meshheading:7768497-Luteinizing Hormone, pubmed-meshheading:7768497-Male, pubmed-meshheading:7768497-Middle Aged, pubmed-meshheading:7768497-Neoplasm Staging, pubmed-meshheading:7768497-Placebos, pubmed-meshheading:7768497-Probability, pubmed-meshheading:7768497-Survival Rate, pubmed-meshheading:7768497-Tamoxifen, pubmed-meshheading:7768497-Time Factors, pubmed-meshheading:7768497-Triptorelin Pamoate
pubmed:year
1995
pubmed:articleTitle
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
pubmed:affiliation
Academic Department of Medicine, Hippokration General Hospital, Athens, Greece.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't